Complementary anti-inflammatory effects of a β-blocker and a corticosteroid in an asthma model

[1]  B. Lipworth,et al.  Response to salbutamol in patients with mild asthma treated with nadolol , 2010, European Respiratory Journal.

[2]  M. Weatherall,et al.  Dose–response relationship of inhaled corticosteroids and cataracts: A systematic review and meta‐analysis , 2009, Respirology.

[3]  B. J. Knoll,et al.  β2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model , 2009, Proceedings of the National Academy of Sciences.

[4]  E. Travis,et al.  Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary disease phenotype. , 2008, American journal of respiratory cell and molecular biology.

[5]  B. J. Knoll,et al.  Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. , 2008, American journal of respiratory cell and molecular biology.

[6]  B. J. Knoll,et al.  Changes in β2-adrenoceptor and other signaling proteins produced by chronic administration of ‘β-blockers’ in a murine asthma model , 2008 .

[7]  M. Flashner,et al.  The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. , 2008, Pulmonary pharmacology & therapeutics.

[8]  Robert J. Lefkowitz,et al.  A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling , 2007, Proceedings of the National Academy of Sciences.

[9]  M. Cazzola,et al.  Safety of inhaled corticosteroids: room for improvement. , 2007, Pulmonary pharmacology & therapeutics.

[10]  B. Stripp,et al.  Mucin is produced by clara cells in the proximal airways of antigen-challenged mice. , 2004, American journal of respiratory cell and molecular biology.

[11]  T. Hansel.  How do we measure the effectiveness of inhaled corticosteroids in clinical studies? , 2004, Respiratory medicine.

[12]  D. Rogers.  Airway mucus hypersecretion in asthma: an undervalued pathology? , 2004, Current opinion in pharmacology.

[13]  Huanzhong Shi.  Eosinophils in asthma. , 2004, Chinese medical journal.

[14]  P. Callaerts,et al.  Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Fahy.  Goblet cell and mucin gene abnormalities in asthma. , 2002, Chest.

[16]  R. Pauwels,et al.  Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.

[17]  C. Bertrand,et al.  Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[18]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[19]  P. Sterk,et al.  Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. , 1996, Thorax.

[20]  N. Hanania,et al.  Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. , 1995, The Journal of allergy and clinical immunology.

[21]  P. Barnes,et al.  Inhaled glucocorticoids for asthma. , 1995, The New England journal of medicine.

[22]  T. Kenakin,et al.  Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the β2-adrenoceptor , 1995, Nature.

[23]  T. Haahtela,et al.  A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. , 1992, The Journal of allergy and clinical immunology.

[24]  C. Corrigan,et al.  The roles of inflammatory cells in the pathogenesis of asthma and of chronic obstructive pulmonary disease. , 1991, The American review of respiratory disease.

[25]  H. Sasaki,et al.  Direct inhibitory action of glucocorticoid on glycoconjugate secretion from airway submucosal glands. , 1990, The American review of respiratory disease.

[26]  R. Schleimer.  Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. , 1990, The American review of respiratory disease.

[27]  P. Barnes,et al.  Effect of corticosteroids on airway hyperresponsiveness. , 1990, The American review of respiratory disease.

[28]  K. Chung,et al.  Inflammatory mediators and asthma. , 1988, Pharmacological reviews.

[29]  Hui Peng,et al.  Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. , 2008, Pulmonary pharmacology & therapeutics.

[30]  J. Violin,et al.  A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Callaerts,et al.  Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Svartengren,et al.  A simple pharmacokinetic method to evaluate the pulmonary dose in clinical practice--analyses of inhaled sodium cromoglycate. , 2004, Respiratory medicine.

[33]  D. L. Maxwell,et al.  Adverse effects of inhaled corticosteroids. , 1990, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.